GLP-1 receptor agonists: the current research landscape
From semaglutide to tirzepatide and beyond, the GLP-1 agonist class has moved rapidly from bench to clinic. A snapshot of where preclinical research is heading next.
The glucagon-like peptide-1 (GLP-1) receptor agonist class has become one of the most studied peptide categories of the last decade. Semaglutide, tirzepatide, and retatrutide have all reached clinical use, and dozens of related molecules remain in preclinical or early-clinical development.
Mechanism at a glance
GLP-1 receptor agonists mimic the endogenous incretin GLP-1, which is secreted by intestinal L-cells after a meal. Activating the GLP-1 receptor amplifies glucose-dependent insulin secretion, slows gastric emptying, and — via central pathways — reduces appetite.
Tirzepatide's dual-agonist twist
Tirzepatide adds a second binding target: the GIP (glucose-dependent insulinotropic polypeptide) receptor. Preclinical models suggest that dual GLP-1/GIP agonism can produce additive effects on body-weight and glycaemic endpoints that single agonism does not achieve alone.
What's next
Triple agonists (GLP-1/GIP/glucagon) like retatrutide are already in advanced trials. Peptide chemists continue to iterate on backbone stability and half-life extension strategies (e.g. fatty-acid conjugation), which have transformed a class that once required daily injection into weekly or even monthly dosing.